MAPT and Cognitive impairment: Notably, [18F]florbetaben was shown to have no binding affinity for tau- or α-synuclein deposits, indicating high specificity for Aβ plaques.62 In 2020, Eli Lilly announced that the FDA had approved [18F]flortaucipir (Tauvid) for brain PET/CT imaging to diagnose AD patients with cognitive impairment.58,63 [18F]Flortaucipir is the first and only approved diagnostic agent for imaging tau-neurofibrillary tangles (NFTs) in the brain.